Clinical Effect of Temozolomide-Based Chemotherapy in Poorly Differentiated Endocrine Carcinoma (PDEC) after Progression on First-Line Chemotherapy


Introduction: Patients with metastatic PDEC usually have a short survival. After first-line palliative chemotherapy, there are no established second-line treatments. Temozolomide has shown effect in other NETs.

Aim(s): This study was performed to evaluate the effect of temozolomide-based chemotherapy in PDEC patients who had progressed on first-line treatment.

Materials and methods: In this retrospective study, 25 patients with PDEC (mainly gastrointestinal) were treated with temozolomide alone or in combination with capecitabine. A subset of patients also received bevacizumab. MGMT methylation was analysed in tissue specimens.

Conference: 8th Annual ENETSConcerence (2011)

Presenting Author:

Authors: Welin S, Sorby H, Sebjornsen S, Knappskog S, Busch C,

Keywords: chemotherapy, neuroendocrine cancer, PDEC, second-line, temozolomide,

To read the full abstract, please log into your ENETS Member account.